AND PHARMA Co., Ltd.

AND PHARMA Co. , Ltd. , based in Tokyo, Japan, collaborates with partners to produce and distribute pharmaceutical products, ensuring a stable supply of safe medications for healthcare providers and patients. Founded in 2025 in Tokyo, Japan, AND PHARMA Co.

, Ltd. is focused on the pharmaceutical sector, pursuing strategic partnerships to enhance its operational capabilities. The company recently completed a deal in October 2025, where Mochida Pharmaceutical acquired a 20% minority stake for JPY 16 billion. The total amount raised by AND PHARMA to date is JPY 16 billion, all from this latest funding round, LP Direct.

This funding has facilitated their operational growth without any changes in business strategy or structure. AND PHARMA Co. , Ltd. specializes in the production and distribution of pharmaceutical products, manufactured through reliable processes that ensure a consistent supply of safe medication.

The company supports the pharmaceutical industry by enhancing the stability of its manufacturing processes and supply chains. Their core offerings address various healthcare needs by providing medications to assist in maintaining public health, improving the quality of life for individuals. AND PHARMA serves a diverse clientele, including healthcare providers, hospitals, and pharmacies, primarily focusing on the Japanese market while seeking expansion into other Asian countries. The end users of their products are patients relying on their medications for chronic and acute health conditions.

AND PHARMA generates revenue through business-to-business transactions with healthcare providers, pharmacies, and hospitals purchasing their pharmaceutical products. The company engages in structured partnerships that enable steady supply agreements, facilitating transactions at negotiated pricing tiers based on volume or contractual terms. While specific pricing plans for their products are not disclosed, AND PHARMA’s offerings are strategically positioned to meet the healthcare market’s demands. Their revenue model encompasses both direct sales and potential collaborations with larger pharmaceutical distributors, enhancing their market presence and financial performance.

In October 2025, AND PHARMA plans to utilize the recent investment from Mochida Pharmaceutical to strengthen its pharmaceutical operations and enhance biosimilar supply. The collaboration aims to foster efficient production and distribution systems that support healthcare. The company is also exploring new product designs and launches, with a focus on expanding into other Asian markets, to be realized in the coming years.